News articles

  • A drop of blood can detect Alzheimer’s – international award

    The 2026 Jeffrey L. Morby Prize has been awarded to researchers from Lund University and Washington University for a... Read more...
  • New blood biomarker reduces the risk of misdiagnosing Alzheimer’s disease.

    The new blood tests for diagnosing Alzheimer’s disease are providing increasingly better opportunities for early diagnosis, but one challenge... Read more...
  • Blood Tests: Not Just for the Impaired?

    In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease... Read more...
  • Looking Good: Immunoassays for Blood Markers

    For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical... Read more...
  • More opportunities to test for Alzheimer’s using new analytical method

    A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
  • Simple, yet effective way to early detect Alzheimer’s disease

    A simpler method of analysing blood samples for Alzheimer’s disease has been tested in a large multicentre study, led... Read more...
Load more

Recent key publications

More publications...

X posts

📢 New preprint from BioFINDER, led by @karlssonlinda1!
We trained a deep learning model to generate synthetic tau-PET 3D scans from more accessible data: structural MRI, plasma p-tau217, and age. https://www.medrxiv.org/content/10.64898/2026.05.06.26352540v1

New paper in @GreenJournal! We investigated whether future AD dementia can be predicted in individuals with subjective cognitive decline. We found that plasma p-tau217, cognitive testing, and APOE ε4 status accurately identify those at highest risk. https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000214983

This study was led by María Rivera Sánchez. A huge thanks to all co-authors: @SEMastenbroek, @NiklasMattsson4, @DaniellevWe, @EStomrud, @SebastianPalmqv, @RikOssenkoppele

This supports the potential of blood-based biological staging as scalable alternative to PET imaging for AD characterization. This approach may improve participant stratification for clinical trials and facilitate broader implementation of biological staging in clinical practice.

A huge thank you to all co-authors and collaborators for their incredible work on this project: @KantaHorie, @SuzanneESchind1, @A_OrdunaDolado, @tlsmit1, @BrianGordon81, @NiklasMattsson4, @SebastianPalmqv, @_JakeVogel_ @RandallBateman3, @RikOssenkoppele, and all not on X.

Using large-scale proteomics across multiple cohorts, we found that APOE ε4 and APOE ε2 have largely distinct protein signatures. Many changes appeared even before detectable Aβ pathology, suggesting that APOE-related molecular alterations may begin long before dementia develops.

A big thanks to all authors and collaborators!
@LuLina000147323, @ines_hristovska, @cumplido_irene, @anlijuncn, @RikOssenkoppele, @SebastianPalmqv, @_JakeVogel_, @EStomrud, @NiklasMattsson4

Big thanks to all authors and collaborators! @LECollij @gesalbla @KantaHorie @tobeybetthauser @ErikRubenSmith @SebastianPalmqv @SuzanneESchind1 @RikOssenkoppele @NiklasMattsson4 @RandallBateman3

This study was led by Beata Borgström Bolmsjö. A big thanks to all collaborators and co-authors: @DaniellevWe @SuzanneESchind1 @LECollij @ErikRubenSmith @NiklasMattsson4 @EStomrud @SebastianPalmqv and all not on X.

New publication out in Brain! 📢We developed a data-driven multimodal biomarker framework to characterize a memory clinic cohort based on the presence, extent, and sequence of common pathologies. This framework may support diagnosis and trial selection.
🔗

Biological classification of memory clinic patients

Mastenbroek et al. present a biological framework developed to categorize individuals in a memory clinic cohort based ...

academic.oup.com

The study was led by @SEMastenbroek, a huge thank you to all co-authors: @LECollij, @teanijarv, @jorittmo, @YoungAlexL, @ErikRubenSmith, @NicolaSpotorno, @SebastianPalmqv, @NiklasMattsson4, @_JakeVogel_, @FBarkhof, @RikOssenkoppele and all not on X.

📢New in The Lancet Neurology!
We validate a two-step blood test for Alzheimer’s disease:
1️⃣ plasma %p-tau217 identifies amyloid-β pathology
2️⃣ plasma eMTBR-tau243 assesses whether AD pathology is causing clinical symptoms
🔗https://www.sciencedirect.com/science/article/pii/S1474442226000293

This study was led by @NiklasMattsson4, huge thanks to all co-authors: @SebastianPalmqv, @KantaHorie, @gesalbla, @tlsmit1, @LECollij, @RikOssenkoppele, @SuzanneESchind1, @EStomrud, @RandallBateman3, and all not on X.

New BioFINDER preprint!
We formalise the Aβ–tau–neurodegeneration (ATN) framework into a mechanism-based model of AD, enabling us to simulate longitudinal imaging biomarkers and study how disease processes evolve and interact across the AD continuum.
🔗https://www.biorxiv.org/content/10.64898/2026.01.27.701320v1

This work was led by @ChaggarPavan, @_JakeVogel_, Niklas Mattsson-Carlgren, Oskar Hansson, @AlainGoriely.  Huge thanks to all coauthors: Travis Thompson, Roxana Aldea, Olof Strandberg, Erik Stomrud, Sebastian Palmqvist, @RikOssenkoppele, @SaadJbabdi, Stefano Magon, Gregory Klein!

Main takeaway:
CSF Ab42/Ab40 and plasma p-tau217 showed distinct contributions when predicting Aβ-PET, improving our understanding of disease progression and guiding how biomarkers can be applied in clinical and research settings.

The study was led by @NiklasMattsson4, @karlssonlinda1, and Weizhong Tang. Thank you to all co-authors: Kaj Blennow, Henrik Zetterberg, @RandallBateman3, @SuzanneESchind1, Nicolas Barthelemy, @SebastianPalmqv, @EStomrud, Shorena Janelidze, and @OskarHansson9.

💡 Takeaway:
• NfL is robust but not sufficient alone in low-prevalence settings.
• Diagnostic and prognostic frameworks should move toward standardized multimodal models integrating fluid #biomarkers with established predictors.
#ALS #MND

The study was led by Atul Kumar. Thank you to all co-authors: @DivyaBali06, @EStomrud, @SebastianPalmqv, @_JakeVogel_, @OskarHansson9, @NiklasMattsson4, and those not on X.

5⃣ In conclusion, our results support the clinical utility of plasma p-tau217 as stand-alone tool for identifying preclinical AD but adding confirmatory CSF/PET would further improve PPVs as needed in many clinical applications.

🎯The use of plasma p-tau217 will reduce resource demands and burdensome procedures accelerating the development and implementation of early AD therapeutics.

🙏Many thanks to all collaborators in this large study including 12 international cohorts: @DivyaBali06 @A_OrdunaDolado @JosephTherr @EStomrud @NiklasMattsson4 @EmmaCoomans @CharlotteTeuni1 @NesrineR95 @JuandoGispert @vincentDore2 @AzadehFeizpour

@DAlcoleaR @sylv_villeneuve @pedrorosaneto @SuzanneESchind1 @RikOssenkoppele @OskarHansson9 with data from @amsterdamumc @BarcelonaBeta @MayoClinicNeuro @mcgillu @prevent_ad @WashUMedADRC @WisconsinADRC… and those not in X.

Load More